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Background. People with diabetes have an increased risk of developing active tuberculosis (TB) and are more likely to have poor 
TB-treatment outcomes, which may impact on control of TB as the prevalence of diabetes is increasing worldwide. Blood transcriptomes 
are altered in patients with active TB relative to healthy individuals. The effects of diabetes and intermediate hyperglycemia (IH) on 
this transcriptomic signature were investigated to enhance understanding of immunological susceptibility in diabetes-TB comorbidity.
Methods. Whole blood samples were collected from active TB patients with diabetes (glycated hemoglobin [HbA1c] ≥6.5%) or 
IH (HbA1c = 5.7% to <6.5%), TB-only patients, and healthy controls in 4 countries: South Africa, Romania, Indonesia, and Peru. 
Differential blood gene expression was determined by RNA-seq (n = 249).
Results. Diabetes increased the magnitude of gene expression change in the host transcriptome in TB, notably showing an in-
crease in genes associated with innate inflammatory and decrease in adaptive immune responses. Strikingly, patients with IH and 
TB exhibited blood transcriptomes much more similar to patients with diabetes-TB than to patients with only TB. Both diabetes-TB 
and IH-TB patients had a decreased type I interferon response relative to TB-only patients.
Conclusions. Comorbidity in individuals with both TB and diabetes is associated with altered transcriptomes, with an expected 
enhanced inflammation in the presence of both conditions, but also reduced type I interferon responses in comorbid patients, sug-
gesting an unexpected uncoupling of the TB transcriptome phenotype. These immunological dysfunctions are also present in indi-
viduals with IH, showing that altered immunity to TB may also be present in this group. The TB disease outcomes in individuals with 
IH diagnosed with TB should be investigated further.
Keywords.  tuberculosis; diabetes; inflammation; hyperglycemia.
Despite much research, precise mechanisms underlying how 
the host immune response controls Mycobacterium tubercu-
losis are still not fully understood. Studies of comorbidity and 
coinfection associated with susceptibility to tuberculosis (TB) 
may provide useful insights. The epidemiological link between 
diabetes and TB has been known for centuries, yet the biolog-
ical mechanisms underlying the association are still unclear [1]. 
People living with diabetes are >3 times more likely to develop 
active TB once infected [2], and are also more likely to have 
poor TB-treatment outcomes [3]. Ninety percent of diabetes 
cases worldwide are type 2 diabetes mellitus (T2DM) [4], char-
acterized by insulin resistance and subsequent insulin insuffi-
ciency. Diabetes prevalence has risen from 108 million in 1980 
to 415 million in 2014, with an estimated 642 million cases 
projected by 2040 [4]. The countries with the greatest number 
of people with diabetes include several countries with concur-
rent high TB burden, such as China, India, Brazil, Indonesia, 
and Bangladesh. The estimated population attributable fraction 
of diabetes for adult TB is estimated at 9%–17% across World 
Health Organization regions [5], surpassing that for human 
 
Received 3 January 2020; editorial decision 6 May 2020; accepted 9 June 2020; published 
online June 13, 2020.
aH. M. D. and J. M. C. contributed equally to this work.
bThe TANDEM Consortium author list is shown in the Notes.
Correspondence: J. M. Cliff, Department of Infection Biology, London School of Hygiene and 
Tropical Medicine, London WC1E 7HT, UK (jackie.cliff@lshtm.ac.uk).
Clinical Infectious Diseases®  2021;72(1):69–78
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the 











egen user on 03 M
ay 2021
70 • cid 2021:72 (1 January) • Eckold et al 
immunodeficiency virus (HIV) in most regions, emphasizing 
the critical need to target this population for TB control.
T2DM is characterized by a decrease in the ability of insulin to 
alter metabolism in target cells, leading to overproduction of in-
sulin, pancreatic β-cell exhaustion, and eventual depletion of in-
sulin, causing impaired glucose tolerance. Excessive glucose has 
toxic effects systemically, on major organs as well as on cells in the 
immune system. Additionally, T2DM is linked with obesity, with an 
increased number of adipocytes and with increased secretion of free 
fatty acids and of proinflammatory cytokines, including tumor ne-
crosis factor–α, interleukin (IL) 1β, and IL-6 [6, 7], from adipocytes. 
In turn, these abnormalities in glucose control, dyslipidemia, and 
the chronic inflammatory response lead to an immune dysfunction 
disorder, affecting the body’s defence to M. tuberculosis. People with 
T2DM have impaired immune cell function, with reduced phago-
cytic ability in response to M. tuberculosis, which is correlated with 
poor glycemic control [8]. Alongside chronic inflammation, in-
cluding elevated circulating proinflammatory cytokines, people with 
T2DM-TB comorbidity have enhanced type 1 [9, 10] and regulatory 
T-cell responses [11] to M. tuberculosis antigens (reviewed in [12]).
Spectrums exist in both TB and T2DM, from latent M. tuber-
culosis infection through subclinical incipient TB to active TB 
disease [13], and from nondiabetes to clinically manifest dia-
betes via intermediate hyperglycemia (IH). Although not com-
pletely sensitive, glycated hemoglobin (HbA1c) measurement 
can determine an individual’s point along this spectrum, with 
the current threshold for diabetes diagnosis at HbA1c ≥6.5%, 
and for intermediate hyperglycemia at HbA1c = 5.7% to <6.5% 
[14]. IH has become an area of interest because it has also been 
shown to be associated with TB [15, 16].
Blood transcriptomic changes in TB patients have been well 
described: Active TB patients are distinct from healthy con-
trols (HCs), exhibiting a neutrophil-derived interferon (IFN) 
[17] and inflammatory response [18] signature. This resolves 
during successful TB drug treatment [19, 20], and the blood 
transcriptome in TB is distinct from that in other diseases [21, 
22]. Blood-based transcriptomic studies of people living with 
diabetes are scarce. A recent study [23] found few differences 
in transcriptomes between TB-only patients and those with 
T2DM and TB comorbidity, although TB patients with IH were 
not defined in this study.
Here, we used an unbiased RNA-seq approach to identify im-
munological pathways that were altered in T2DM-TB comor-
bidity compared to TB only, and we also investigated the impact 
of IH on TB, in order to understand why diabetes increases sus-




Adults with newly diagnosed, bacteriologically confirmed 
pulmonary TB with and without diabetes were recruited 
between December 2013 and February 2016 at 4 different study 
sites: Cape Town, South Africa (SUN); Bandung, Indonesia 
(UNPAD); Lima, Peru (UPCH); and Craiova, Romania 
(UMFCV). In South Africa and Romania, people with diabetes 
mellitus (DM) but without TB and healthy individuals were also 
recruited. Patients were excluded if they were already taking 
TB treatment, had multidrug-resistant TB, were HIV positive, 
were pregnant, were taking corticosteroids, or had other serious 
comorbidity. DM was classified as a laboratory test of HbA1c 
≥6.5%, alongside a confirmatory HbA1c ≥6.5% or fasting 
blood glucose ≥7  mmol/L, as described in this cohort [24]. 
Patients with IH were characterized with an HbA1c reading of 
5.7% to <6.5%. Patients without diabetes, including HCs, had 
HbA1c values of <5.7%. All patients gave written informed 
consent, and the study was approved by the London School of 
Hygiene and Tropical Medicine Observational/Interventions 
Research Ethics Committee (6449, 11 July 2013) as well as the 
SUN Health Research Ethics Committee (N13/05/064, 29 July 
2013), the UNPAD Health Research Ethics Committee, Faculty 
of Medicine, Universitas Padjadjaran (number 377/UN6.
C2.1.2/ KEPK/ PN/2012), the UMFCV Committee of Ethics 
and Academic and Scientific Deontology (94, 6 September 
2013), and the UPCH Institutional Committee of Ethics in 
Investigation (61069, 2 September 2013).
To limit confounding, prior to conducting the RNA-seq 
analysis, patient characteristic variables (age, body mass index 
[BMI], HbA1c) for each clinical group and for each study setting 
were initially tested using analysis of variance. Subsequently, 
variables were tested for normality using the Shapiro-Wilk 
test: If deemed normally distributed, a pairwise t test was per-
formed, if not, a nonparametric Wilcoxon rank-sum test was 
performed. The participant ethnicities were recorded.
RNA-seq Experiments
Venous blood was collected at TB diagnosis, before initiation of 
TB treatment, into PAXgene Blood RNA Tubes (PreAnalytiX) 
and used for RNA-seq analysis, using the polyA tail library 
preparation method and single-read sequencing (n  =  249). 
Sequencing FASTQ files were aligned to the human genome, 
and transcript quantification, differential gene expression, bi-
ological characterization, and machine learning were per-
formed as described in the Supplementary Methods. RNA-seq 




A total of 151 TB patients were recruited from 4 locations 
in South Africa, Romania, Indonesia, and Peru, and clas-
sified as having TB only, IH-TB, or DM-TB, depending 
on laboratory HbA1c results at the time of TB diagnosis 
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previously diagnosed DM, some of whom were taking insulin 
(Supplementary Table 2). Additionally, in South Africa and 
Romania, individuals without disease (HCs) and DM only 
were recruited. The ages of the participants were not signif-
icantly different across the disease categories in any site or 
when the sites were combined (median age: 46 years for TB 
only; 46 years for IH-TB; and 49 years for DM-TB; Table 1). 
As anticipated, the BMI was significantly greater in the 
DM patients than in all the other patient groups at all sites 
(Table 1). Overall, participants had 10 different stated ethnic 
backgrounds, but the participants’ ethnicities were not dif-
ferent across disease groups within each site.
Blood TB Transcriptome Signature
First, the effect of DM and IH on gene expression changes in TB 
patients’ blood was investigated in South African samples. As 
expected, there was substantial up-regulation of gene expres-
sion (345 genes) in TB patients compared to HCs (Figure 1A), 
including up-regulated expression of genes such as comple-
ment component C1QA, B, C, and C2; BATF2; SOCS3; Septin 
4; ANKRD22; and GBP5, which have been observed previously 
[20, 25, 26] (Figure 1A). Diabetes alone had a very different im-
pact on the blood transcriptome, with larger numbers of genes 
differentially expressed, but with low magnitude of change and 
lower statistical significance (Figure 1B). In contrast, DM had a 
substantial impact on the blood transcriptome in TB patients, 
with 1695 genes significantly up-regulated in DM-TB patients 
compared to HCs, including many ribosomal and transmem-
brane proteins, as well as proinflammatory cytokines such as 
IL-1β, IL-15, and IL-18 and the regulatory cytokine IL-10. 
There were also 1623 genes significantly down-regulated in the 
DM-TB group compared to HCs, including several zinc finger 
transcription factors and cytokines such as IL-8, IL-16, and 
IL-24. Notably, patients with IH-TB exhibited an even greater 
perturbation of their blood transcriptome relative to HCs, with 
2576 genes significantly up-regulated and 2140 genes signifi-
cantly down-regulated (Figure 1D). These results show that di-
abetes impacts the peripheral host response to TB and that this 
effect is already present in individuals with IH. Supplementary 
Table 3 details all of the differentially expressed genes in the 
South African cohort. Supplementary Figure 2 shows that sex 
had no impact on gene expression differences.
These data were validated in a separate patient cohort, re-
cruited in Romania. Similarly large-scale up- and down-
regulation of gene expression in both DM-TB and IH-TB were 
observed relative to HCs, to a much greater extent than that 
seen in TB only (Supplementary Figure 3). Direct compar-
ison of differentially expressed gene lists in South Africa and 
Romania showed significant overlap in each case (GeneOverlap 
P < .05; Supplementary Figure 4).
Table 1.  Characteristics of Study Participants
Characteristic Country TB Only IH-TB DM-TB T2DM Only Healthy Controls P Value (ANOVA)
No. of study participants South Africa 11 20 15 33 24  
Romania 10 10 15 19 12  
Indonesia 14 5 19 … …  
Peru 11 9 12 … …  
All sites 46 44 61 … …  
Age, y, median (range) South Africa 48 (31–56) 44.5 (25–57) 46 (27–57) 49 (29–64) 42 (30–70) .168
Romania 43 (30–64) 48.5 (22–63) 47 (22–64) 55 (38–65) 46 (38–61) .329
Indonesia 47 (28–62) 51 (37–54) 52 (33–66) … … .430
Peru 55 (31–69) 52 (31–68) 50.5 (42–58) … … .928
All sites 46 (28–69) 46 (22–68) 49 (22–66) … … .2645
Sex, % (No. male/female) South Africa 18 (2/9) 60 (12/8) 47 (7/8) 45 (15/18) 50 (12/12)  
Romania 60 (6/4) 90 (9/1) 87 (13/2) 73 (14/5) 83 (10/2)  
Indonesia 50 (7/7) 80 (4/1) 58 (11/8) … …  
Peru 45 (5/6) 55 (5/4) 50 (6/6) … …  
All sites 43 (26/20) 68 (30/14) 60 (37/24) … …  
BMI, kg/m2, median (range) South Africa 20.1 (14.6–24.1) 18.4 (13.7–27.1) 19.1 (13.9–32.3) 29 (20.52–52.54) 23.7 (17.37–45.20) 1.43x10[-8]
Romania 20.65 (17.7–25.5) 21 (15.5–22) 21.5 (15.3–36.1) 28.7 (13.1–37.8) … 6.73x10[-4]
Indonesia 19.8 (13.76–33.27) 18.67 (13.9–20.09) 19.52 (16.10–31.73) … … .242
Peru 23.98 (17.35–28.96) 21.94 (18.67–25.56) 22.7 (20.55–33.33) … … .207
All sites 20.94 (13.76–33.27) 19.44 (13.7–27.1) 21.5 (13.9–36.1) … … 1.67x10[-3]
HbA1c, %, median (range) South Africa 5.3 (4.8–5.7) 6 (5.7–6.3) 10.8 (6.5–14.3) 10.1 (4.7–14.9) 5.3 (4.8–5.6) 2.2x10[-16]
Romania 5.5 (5.2–5.7) 6 (5.7–6.4) 10.4 (6.6–15) 9 (7.1–14) 5.4 (5.2–5.6) 1.2x10[-13]
Indonesia 5.55 (5–5.7) 5.9 (5.8–6) 11.9 (7.5–15.9) … … 3.2x10[-12]
Peru 5.3 (5.1–5.7) 5.8 (5.7–6.1) 11.4 (7.1–15.2) … … 8.33x10[-9]
All sites 5.5 (4.8–5.7) 5.95 (5.7–6.4) 11 (6.5–15.9) … … 2.2x10[-16]
Abbreviations: ANOVA, analysis of variance; BMI, body mass index; DM-TB, diabetes mellitus–tuberculosis; HbA1c, glycated hemoglobin; IH-TB, intermediate hyperglycemia–tuberculosis; 
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Log fold change (FC)–FC plots demonstrate concordant and 
discordant differential expression of genes when samples in dif-
ferent disease categories are compared to controls; discordant 
genes show significant differences in both comparisons, yet in 
opposite directions, whereas concordant genes show significant 
differences in both comparisons in the same direction. Here, 
all 4 disease groups with HCs in the South African cohort were 
compared (Figure 2). The main differences, showing the most 
discordance, were seen between the DM-only group vs HC 
comparison against all 3 comparisons of patients with TB (TB 
only vs HCs; DM-TB vs HCs; and IH-TB vs HCs), showing that 
the TB transcriptome is dominant. The greatest concordance 
was between DM-TB vs HCs and IH-TB vs HCs, showing that 
patients in these categories exhibited similar changes in blood 
gene expression. The comparison between TB only vs HCs and 
IH-TB vs HCs showed quantitative differences, with concord-
ance between the genes but to a larger degree in the IH-TB 
group, indicating extra perturbation when hyperglycemia is 
present (Figure 2).
To determine whether differential gene expression could be 
used to discriminate disease phenotype, principal component 
analysis (PCA) was performed on all study participants from 
South Africa. The resulting PCA plot, based on the differentially 
expressed genes from the initial analysis, showed 2 main clus-
ters: HCs and people with DM only clustered together, while the 
second main cluster comprised people with IH-TB and DM-TB 
comorbidity (Figure 3).
Modular Analysis in DM and TB Comorbidity
Modular analysis, which tests for enrichment sets of 
co-regulated genes sharing related biological functions 
[27, 28], was performed. As observed previously [17, 20], 
in the South African cohort, TB-only patients exhibited 
up-regulation of specific modules, including the type I  IFN 
Figure 1. Differential expression analysis of all the disease phenotypes in South Africa compared to healthy controls before the initiation of tuberculosis (TB) treatment. 
Gene expression profiles of TB only (n = 11, A), diabetes mellitus (DM) only (n = 33, B), DM-TB (n = 15, C), and intermediate hyperglycemia (IH)–TB (n = 20, D), each relative 
to healthy controls (n = 24). Genes that were deemed statistically significantly differentially expressed had an adjusted P < .05 after multiple testing correction (Benjamini-
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response, complement, and activated dendritic cells (Figure 4 
and Supplementary Figure 5). In contrast, in diabetes pa-
tients, mainly respiration and protein synthesis modules were 
significantly up-regulated compared to HCs; these changes 
were not present in the comorbidity groups. Notably, module 
enrichments in DM-TB and IH-TB patients were similar to 
each other, which included up-regulation of modules differ-
entially expressed in the TB-only group with a greater mag-
nitude, especially for modules related to the inflammatory 
response and to myeloid cell function. There was stronger 
down-regulation of modules in IH-TB and DM-TB groups 
compared to TB only: these included natural killer (NK) cell 
modules and adaptive immune response modules such as 
T-cell activation, differentiation, and B cells (Figure 4).
Figure 2. Concordance and discordance of gene expression between the comparisons of each disease group and healthy controls in South Africa. Log fold change (FC) and P value 
between groups was calculated with R-package DESeq2. A disco.score was calculated for each pair of corresponding genes. The axes show log2 FC between the conditions indicated 
by the labels. For example, on the top left plot the x-axis corresponds to the comparison between tuberculosis (TB) and healthy controls (HC), and the y-axis shows the log2 FC between 
diabetes mellitus (DM)-TB and HC. Red dots show genes that are significantly different from the controls in the same direction (concordant genes), and blue dots show genes that are 
significantly different in both comparisons, but in opposite directions. Intensity of color indicates the strength of concordance/discordance as measured by the disco.score.
Figure 3. Principal component analysis (PCA) of South African participants. The 
list of all genes that were significantly differentially expressed in any patient group 
comparison with healthy controls was used in a PCA of all the samples obtained 
from participants recruited in South Africa. Abbreviations: DM, diabetes mellitus; 
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Figure 4. Transcriptional modules that were significantly differentially expressed in tuberculosis (TB)-only, diabetes mellitus (DM)-TB, intermediate hyperglycemia (IH)-TB, 
and DM only compared to healthy controls in South Africa before initiation of TB treatment. Transcripts were evaluated using a preexisting modular framework. Significantly 
up-regulated (red) and down-regulated (blue) modules are shown: the length of each bar corresponds to the effect size (magnitude of change) of that module, and the color 
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Interferon and Inflammatory Responses
To determine the reproducibility of results across geographical 
regions and different patient ethnicities, RNA-seq data from 
DM-TB, IH-TB, and TB-only patients from all 4 study sites were 
combined. There was no systematic bias due to sample origin 
site (Supplementary Figure 6). In the combined dataset, DM-TB 
and IH-TB patients showed similar altered gene expression pat-
terns in blood compared to patients with TB only (Figure 5). 
DM-TB patients had 292 up-regulated and 130 down-regulated 
genes, whereas IH-TB patients had 432 up-regulated and 126 
down-regulated genes (Supplementary Table 4).
In modular analysis, both DM-TB and IH-TB showed a 
general trend of up-regulation, especially of modules in-
volved in inflammation. Interestingly, however, patients with 
DM-TB and IH-TB also exhibited down-regulation of several 
IFN modules compared to TB only (Supplementary Figure 
7). The most significantly differentially expressed are shown 
in Figure  6. The genes within these modules were differen-
tially expressed in DM-TB and IH-TB, but of a greater mag-
nitude in DM-TB, indicating an association with the extent of 
hyperglycemia.
Transcriptomic Signatures
We applied known Kaforou et  al [29] and Sweeney et  al [30] 
TB biomarker signatures that could distinguish TB from latent 
TB infection, to test validity in DM patients, using the random 
forest algorithm. As expected, the Kaforou signature validated 
well in our TB-only dataset (area under the curve [AUC] = 0.96; 
Figure 7, blue line). However, in the DM-TB comorbidity cohort, 
the performance was significantly reduced for both Kaforou 
(AUC = 0.87; Figure 7, orange line, test for difference between 
receiver operating characteristic [ROC] curves, P =  .018) and 
Sweeney (AUC = 0.84; Figure 7, green line) signatures. This im-
plies that a TB biomarker signature for use in the general popu-
lation needs to be derived from patient cohorts including those 
with DM. ROC curves showing sensitivities and specificities for 
these comparisons are shown in Supplementary Table 5.
DISCUSSION
The principal finding of this study was that DM comorbidity 
influences blood transcriptomes in patients with TB, weak-
ening the performance of published TB biosignatures. Of po-
tentially greater public health importance, the modulation seen 
with diagnosed DM was also evident in those with intermediate 
hyperglycemia, below the current HbA1c cutoff for DM diag-
nosis. There was greater up-regulation of genes involved in the 
inflammatory response in diabetes and TB comorbidity and 
also a reduced up-regulation of the IFN response, principally of 
genes in the type I IFN pathway.
Figure 5. Differential gene expression analysis of diabetes mellitus (DM)–tuberculosis (TB) and intermediate hyperglycemia (IH)–TB patients relative to TB-only patients, in 
the combined dataset from all 4 field sites. Samples collected in South Africa, Romania, Peru, and Indonesia from DM-TB (A) patients and IH-TB patients (B) were compared 
with patients with TB only in a combined analysis. Genes significantly differentially expressed after multiple testing correction are shown in black (P < .05). Genes in gray are 
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IH-TB patients were more similar to DM-TB patients than 
to people with TB only, even though their hyperglycemia was 
below the diabetes diagnostic threshold. Separation of the TB 
patients with HbA1c <6.5% facilitated the discovery of differ-
ences between the groups, which was not clearly evident in a 
previous transcriptomics study [23]. Our results demonstrate 
that patients with intermediate levels of hyperglycemia exhibit 
immune dysfunction, which could lead to an increased sus-
ceptibility to active TB disease. It was previously proposed that 
adverse effects and disease susceptibility would occur at higher 
HbA1c values, later in diabetes progression [31]. Infectious dis-
eases, including TB, can themselves induce transient hypergly-
cemia [32] and poor outcome; further studies are warranted to 
establish the interplay between glycemic control, TB, and im-
mune dysfunction. Targeted control of diabetes in TB could 
lead to better TB outcomes, and analysis of the direct impact of 
glycemic control in immune dysfunction is merited.
Developing TB control strategies targeting people with diabetes 
is critical, due to the rapidly increasing global T2DM burden, espe-
cially in countries with high TB incidence [33]. People living with 
diabetes have an increased risk of developing active TB following 
infection [34], and therefore this patient group may contribute dis-
proportionately to onward TB transmission. DM-TB comorbidity is 
more likely to result in poor TB treatment outcomes [3], including 
failure and relapse, adding an extra burden on healthcare systems. 
Globally, population level diabetes interventions might provide ef-
fective TB control strategies [35].
In a parallel study conducted within the TANDEM 
Consortium analysis involving patients from the same 4 coun-
tries, TB patients with IH as well as with DM were more likely 
to be sputum smear positive compared to normoglycemic TB 
controls [24]. The impact of IH on TB disease susceptibility has 
been less well investigated, but in 2 studies conducted in India 
[15, 36] and 1 in Kenya [37], both IH and diabetes prevalences 
Figure 6. Summary of modular analysis in all 4 field sites. The fold changes of the genes within the top significantly differentially expressed modules are shown (adjusted 
P < .05). Inside: intermediate hyperglycemia–tuberculosis (TB) compared to TB only. Outside: diabetes mellitus–TB compared to TB only. Up-regulated genes are shown in 
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in patients with pulmonary TB were substantially higher than 
in the general population, indicating that IH is also associated 
with the development of active TB. Our data strongly indicate 
that immune abnormalities occurring in DM-TB are already 
present in IH-TB, and it is possible that existing altered immune 
function in hyperglycemia underlies the epidemiological link.
This study shows that TB patients with either IH or diabetes have 
an altered immune phenotype, characterized by an excessive inflam-
matory response and a reduced type I IFN response. Both TB [18] 
and DM are proinflammatory conditions, and a degree of synergy 
between the 2 diseases is likely responsible for driving lung pathology 
and clinical symptoms. In active TB only, type I IFN response genes 
are up-regulated compared to healthy infected and uninfected in-
dividuals [17, 20, 22, 38]. Although surmised to be a deleterious 
excessive response in TB-only patients, the reduced IFN response 
seen in IH-TB and DM-TB patients might indicate an insufficient 
response, permitting continued growth of mycobacteria. Several 
IFN-related modules were present in the analysis performed, con-
taining overlapping gene sets including genes encoding proteins in-
volved in both type I and type II IFN pathways, all of which were all 
less up-regulated in the IH-TB and DM-TB groups compared to TB 
alone. The balance between inflammatory and type I IFN responses 
is critical for control of M. tuberculosis [39], and our finding reveals a 
potential mechanism of TB susceptibility in IH as well as in diabetes 
patients. Further work is required to confirm whether the type II IFN 
response is also affected, although we noted greater down-regulation 
of T-cell and NK-cell modules in IH-TB and DM-TB compared to 
TB alone. A recent study performed in Pakistan found raised serum 
concentrations of IFN-γ and IL-13 in both IH-TB and DM-TB, al-
though TB patients with up to 1 month of anti-TB therapy were in-
cluded [40]. Further work could also include an analysis of regulatory 
microRNAs and long noncoding RNAs, to understand better the 
mechanisms underpinning altered transcriptomes and immune re-
sponses in DM-TB.
Immunological differences in DM-TB compared to TB only in-
clude enhanced proinflammatory responses [12], and increased cir-
culating cytokines have also been described in IH-TB [41]. Immune 
abnormalities are detectable in individuals latently infected with 
M. tuberculosis with IH [42], and it is possible that concurrent inter-
mediate hyperglycemia and latent TB infection drives the develop-
ment of both diseases, in a similar manner to the synergism between 
TB and HIV disease. This may indicate a relationship between mod-
erate HbA1c values and TB susceptibility that warrants careful clinical 
considerations, and investigation of clinical disease outcome.
To conclude, these data have uncovered an enhanced inflamma-
tory profile together with decreased IFN responses, associated with 
DM-TB comorbidity, which may be responsible for the increased 
susceptibility to TB in people with diabetes. Furthermore, immune 
dysfunction exists even at intermediate levels of hyperglycemia, po-
tentially causing TB susceptibility with implications for TB control. 
HbA1c values need to be considered in TB studies, as abnormal gly-
cemia clearly affects the immune response.
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